Pharmaceutical As to be expected, the novel coronavirus continued to dominate the news last week, including Gilead Sciences’ decision to ramp up production and research of its COVID-19 candidate remdesivir, as well as gifting 1.5 million doses. Also, global plasma leaders, including Takeda and CSL Behring, are collaborating on a possible hyperimmune therapy for COVID-19. Additionally, GlaxoSmithKline and Vir Biotechnology announced that their collaboration would prioritize coronavirus drugs, notably VIR-7831 and VIR-7832. Elsewhere, Millendo Therapeutics suffered a blow on Monday, when its rare disease drug livoletide failed to meet Phase IIb goals and leading to the company terminating the PWS program. 12 April 2020